Sinopharm Capital contributed to a series A-plus round raised two months after ABM began enrolling patients for a phase 1 trial of its cancer drug candidate.
China-based oncology drug developer ABM Therapeutics has secured $20m in series A-plus funding from investors including Sinopharm Capital, an investment vehicle for pharmaceutical company Sinopharm, China Money Network has reported.
Venture capital firm China Growth Capital led a round that also featured private equity firm Panlin Capital, investment manager Kaitai Capital, VC firm Ming Bioventures and a pharmaceutical investor known as LongDAC.
Founded in 2015, ABM is developing small molecule therapeutics to treat brain cancer in addition to brain metastasis…
